ES2184092T3 - Inhibicion de metaloproteasas de la matriz por acidos 2-(omega-aroialquil)-e-biaril-4-oxobutiricos. - Google Patents

Inhibicion de metaloproteasas de la matriz por acidos 2-(omega-aroialquil)-e-biaril-4-oxobutiricos.

Info

Publication number
ES2184092T3
ES2184092T3 ES97924788T ES97924788T ES2184092T3 ES 2184092 T3 ES2184092 T3 ES 2184092T3 ES 97924788 T ES97924788 T ES 97924788T ES 97924788 T ES97924788 T ES 97924788T ES 2184092 T3 ES2184092 T3 ES 2184092T3
Authority
ES
Spain
Prior art keywords
periodistics
periodialnisis
periodalism
states
metaloproteases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97924788T
Other languages
English (en)
Inventor
William J Scott
Margaret A Popp
David S Hartsough
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Corp
Original Assignee
Bayer AG
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Bayer Corp filed Critical Bayer AG
Application granted granted Critical
Publication of ES2184092T3 publication Critical patent/ES2184092T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/63—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/88—Unsaturated compounds containing keto groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SUMINISTRA COMPOSICIONES FARMACEUTICAS Y METODOS PARA TRATAR CIERTOS ESTADOS QUE COMPRENDEN : ADMINISTRACION DE UNA CANTIDAD DE UN COMPUESTO O COMPOSICION DE LA INVENCION QUE SEA EFECTIVA PARA INHIBIR LA ACTIVIDAD DE, AL MENOS, UNA METALOPROTEASA DE LA MATRIZ, OBTENIENDOSE COMO RESULTADO EL EFECTO DESEADO. DICHOS COMPUESTOS O COMPOSICIONES SE REPRESENTAN MEDIANTE LA FORMULA GENERAL (I), DONDE: NI ES 1, 2, 3, O 4 Y AR REPRESENTA UNA FRACCION AROMATICA SUSTITUIDA. DICHOS COMPUESTOS SON UTILES PARA INHIBIR METALOPROTEASAS DE LA MATRIZ Y POR TANTO, COMBATIR ESTADOS A LOS CUALES CONTRIBUYEN DICHAS METALOPROTEASAS, COMO SON LA OSTEOARTRITIS, LA ARTRITIS REUMATOIDE, ARTRITIS SEPTICA, ENFERMEDADES PERIODONTALES, ULCERA CORNEAL, PROTEINURIA, ENFERMEDAD AORTICA ANEURISMAL, EPIDERMOLISIS DISTROFICA, BULOSA, ESTADOS QUE CONDUCEN A RESPUESTAS INFLAMATORIAS, OSTEOPENIAS MEDIADAS POR LA ACTIVIDAD MMP, ENFERMEDAD DE LA ARTICULACION TEMPOROMAXILAR, ENFERMEDADES DESMIELINIZANTES DEL SISTEMA NERVIOSO, METASTASIS TUMORALES O LESION TRAUMATICA DE ARTICULACION SEGUIDA POR PERDIDA DEGENERATIVA DE CARTILAGOS Y TROMBOSIS CORONARIA A PARTIR DE LA RUPTURA DE UNA PLACA ATEROESCLEROTICA. LA PRESENTE INVENCION TAMBIEN SUMINISTRA COMPOSICIONES FARMACEUTICAS Y METODOS PARA TRATAR TALES ESTADOS.
ES97924788T 1996-05-15 1997-05-12 Inhibicion de metaloproteasas de la matriz por acidos 2-(omega-aroialquil)-e-biaril-4-oxobutiricos. Expired - Lifetime ES2184092T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64502996A 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
ES2184092T3 true ES2184092T3 (es) 2003-04-01

Family

ID=24587374

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97924788T Expired - Lifetime ES2184092T3 (es) 1996-05-15 1997-05-12 Inhibicion de metaloproteasas de la matriz por acidos 2-(omega-aroialquil)-e-biaril-4-oxobutiricos.

Country Status (22)

Country Link
EP (1) EP0904260B1 (es)
JP (1) JP3524556B2 (es)
CN (1) CN1119313C (es)
AR (1) AR007099A1 (es)
AT (1) ATE224350T1 (es)
AU (1) AU715877B2 (es)
BR (1) BR9709078A (es)
CA (1) CA2254750C (es)
CO (1) CO5011071A1 (es)
DE (1) DE69715619T2 (es)
ES (1) ES2184092T3 (es)
HN (1) HN1997000070A (es)
HR (1) HRP970242A2 (es)
ID (1) ID17938A (es)
PA (1) PA8429601A1 (es)
PE (1) PE66198A1 (es)
SV (1) SV1997000038A (es)
TN (1) TNSN97081A1 (es)
TW (1) TW457231B (es)
WO (1) WO1997043240A1 (es)
YU (1) YU18397A (es)
ZA (1) ZA974028B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
EP1031349A1 (en) * 1999-02-25 2000-08-30 Bayer Aktiengesellschaft Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases
CA2944614A1 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases
EP3126339A1 (de) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung
JP2017511319A (ja) 2014-04-03 2017-04-20 バイエル ファーマ アクチエンゲゼルシャフト キラル２，５−ジ置換されたシクロペンタンカルボン酸誘導体およびそれの使用
CN116687925A (zh) * 2022-11-04 2023-09-05 中国科学院遗传与发育生物学研究所 一种侵蚀性蛋白酶抑制剂及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS243570B1 (en) * 1984-08-31 1986-06-12 Miroslav Kuchar Omega-aryloxoalkane acids
GB9101468D0 (en) * 1991-01-23 1991-03-06 Ciba Geigy Coating compositions
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors

Also Published As

Publication number Publication date
PE66198A1 (es) 1998-10-23
CO5011071A1 (es) 2001-02-28
ID17938A (id) 1998-02-12
CA2254750A1 (en) 1997-11-20
BR9709078A (pt) 1999-08-03
AU715877B2 (en) 2000-02-10
DE69715619T2 (de) 2003-01-16
AU3010497A (en) 1997-12-05
PA8429601A1 (es) 2000-05-24
TNSN97081A1 (fr) 2005-03-15
EP0904260B1 (en) 2002-09-18
ZA974028B (en) 1998-02-19
CA2254750C (en) 2003-09-30
JP3524556B2 (ja) 2004-05-10
HRP970242A2 (en) 1998-04-30
DE69715619D1 (de) 2002-10-24
CN1119313C (zh) 2003-08-27
SV1997000038A (es) 1998-09-01
JP2001509783A (ja) 2001-07-24
AR007099A1 (es) 1999-10-13
HN1997000070A (es) 1997-09-08
TW457231B (en) 2001-10-01
WO1997043240A1 (en) 1997-11-20
YU18397A (en) 1999-11-22
ATE224350T1 (de) 2002-10-15
CN1234791A (zh) 1999-11-10
EP0904260A1 (en) 1999-03-31

Similar Documents

Publication Publication Date Title
AU754113B2 (en) Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
EP0031954A2 (de) Neue Sulfonamide, Verfahren zu deren Herstellung sowie diese Verbindungen enthaltende Arzneimittel
BR0010555A (pt) Inibidores de neuraminidases
AR001999A1 (es) Derivados de acido carboxilico y composiciones conteniendolos, utiles como inhibidores de metaloproteasa de matriz, y procesos para su preparacion.
BR0316606A (pt) Derivados de aminoindazóis e sua utilização como inibidores de quinases
NO2017045I1 (no) Farmasøøytisk preparat inneholdende 2-(2-nitro-4-ifluormetylbenzoyl)-1,3-cykloheksandion eller et farmasøytisk godtagbart salt derav
PA8429701A1 (es) Inhibicion de las metaloproteasas de matriz por acidos biariloxobutiricos sustituidos
ES2184092T3 (es) Inhibicion de metaloproteasas de la matriz por acidos 2-(omega-aroialquil)-e-biaril-4-oxobutiricos.
DE3610643A1 (de) Neue phenoxyalkylcarbonsaeure-derivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
PA8429301A1 (es) Biarilacetilenos como inhibidores de la metaloproteasa de matriz.
ES2188943T3 (es) Inhibicion de las metaloproteasas de matriz mediante compuestos de fenetilo sustituidos.
US5668172A (en) Anthraquinone pharmaceutical compounds and uses therefor
DE60124148T2 (de) Kalzilytische verbindungen
BRPI0416402A (pt) ácidos tetrÈnico e tetrámico como inibidores de beta-secrease
DE3888394T2 (de) Phenolische Thioäther, Sulfoxide und Disulfide als Hemmstoffe der 5-Lipoxigenase.
OA06730A (fr) Dérivés 3-(buta-1',3'-diényl) substitué de l'acide cyclopropane-1-carboxylique, leur application contre les parasites des végétaux et des animaux à sang chaud, les compositions correspondantes ainsi que les compositions parfumantes les renfermant, leur pré
AR007096A1 (es) Compuesto inhibidor de la metaloproteasa de matriz metodo para inhibir su actividad, una composicion que lo contiene y uso de dichos compuestos para preparar composiciones farmaceuticas
BR9915127A (pt) Derivados de cistina como agentes terapêuticos para doenças relacionadas a metaloprotease de matriz
Gershoff Biological Effects of Methionine Sulfoximine II. Comparative Sulfur Metabolism Studies in Rats and Rabbits
CA2289676A1 (en) Prophylactic/therapeutic agents for atherosclerosis
Raina Part A. Synthesis of Second Generation Dillapiol and Sesamol Analogues; Inhibition of Cytochrom P450 3A4. Part B. Synthesis of Analogs of Z02; Compounds with Potential to Help Regenerate Partially Severed Spinal Cords
KR100527876B1 (ko) 임페레이토린 및/또는 팔카린다이올을 유효 성분으로 함유하는 경련성 질환의 예방 및 치료용 조성물
ECSP972111A (es) Inhibidores de la metaloproteinasas de matriz por acidos 2-(aroilalquil)-4 biaril-4- oxobutiricos
US3927071A (en) Salicylanilides
CA3206649A1 (en) Substituted resorcylic acid compounds in the management of ageing and related disorders